DURHAM, N.C., June 21, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) announced today that its common stock has been approved for secondary listing on the SIX Swiss Exchange in addition to its listing on the NASDAQ Capital Market. Bank am Bellevue of Zurich is acting as the company’s listing agent.
